The primary purpose of this pilot study is to determine the pharmacokinetic (PK) parameters
and collect preliminary safety data for pravastatin when used as a prophylactic daily
treatment in pregnant women at high risk of preeclampsia.
Phase:
Phase 1
Details
Lead Sponsor:
The University of Texas Medical Branch, Galveston
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Northwestern University University of Pittsburgh University of Texas